{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:52:37Z","timestamp":1782276757717,"version":"3.54.5"},"reference-count":25,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,6,15]]},"DOI":"10.2169\/internalmedicine.4323-19","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T22:05:43Z","timestamp":1584569143000},"page":"1535-1539","source":"Crossref","is-referenced-by-count":9,"title":["SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes"],"prefix":"10.2169","volume":"59","author":[{"given":"Kenta","family":"Nonomura","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology, Graduate School of Medicine, Gifu University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Iizuka","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Graduate School of Medicine, Gifu University, Japan"},{"name":"Center for Nutritional Support and Infection Control, Gifu University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Kuwabara-Ohmura","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Graduate School of Medicine, Gifu University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yabe","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Graduate School of Medicine, Gifu University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int Suppl 3(Suppl 2011): 63-72, 2013.","DOI":"10.1038\/kisup.2012.65"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383-393, 2003.","DOI":"10.1056\/NEJMoa021778"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Wanner C, Inzucchi SE, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375: 323-334, 2016.","DOI":"10.1056\/NEJMoa1515920"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Neal B, Perkovic V, Mahaffey KW, et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644-657, 2017.","DOI":"10.1056\/NEJMoa1611925"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375: 1834-1844, 2016.","DOI":"10.1056\/NEJMoa1607141"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mann JFE, \u00d8rsted DD, Brown-Frandsen K, et al.; LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377: 839-848, 2017.","DOI":"10.1056\/NEJMoa1616011"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Wiviott SD, Raz I, Bonaca MP, et al.; DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380: 347-357, 2019.","DOI":"10.1056\/NEJMc1902837"},{"key":"8","unstructured":"8. Gerstein HC, Colhoun HM, Dagenais GR, et al.; REWIND Investigators. Dulaglutide and renaloutcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 394: 131-138, 2019."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab 19: 1353-1362, 2017.","DOI":"10.1111\/dom.12982"},{"key":"10","unstructured":"10. Nagahisa T, Saisho Y. Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 Diabetes. Diabetes Ther 10: 1733-1752, 2019."},{"key":"11","unstructured":"11. Krolewski AS, Skupien J, Rossing P, Warram JH. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int 91: 1300-1311, 2017."},{"key":"12","unstructured":"12. Krolewski AS. Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care 38: 954-962, 2015."},{"key":"13","unstructured":"13. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393: 31-39, 2019."},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54: 965-978, 2011.","DOI":"10.1007\/s00125-010-2028-x"},{"key":"15","unstructured":"15. Fujita H, Morii T, Fujishima H, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int 85: 579-589, 2014."},{"key":"16","unstructured":"16. von Scholten BJ, Persson F, Rosenlund S, et al. Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. Diabetes Obes Metab 19: 901-905, 2017."},{"key":"17","unstructured":"17. Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Investig 4: 108-130, 2013."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hirakawa Y, Tanaka T, Nangaku M. Renal hypoxia in CKD; pathophysiology and detecting methods. Front Physiol 8: 99, 2017.","DOI":"10.3389\/fphys.2017.00099"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ito M, Tanaka T. The anticipated renoprotective effects of sodium-glucose cotransporter 2 inhibitors. Intern Med 57: 2105-2114, 2018.","DOI":"10.2169\/internalmedicine.9842-17"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kamezaki M, Kusaba T, Komaki K, et al. Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice. Sci Rep 8: 4029, 2018.","DOI":"10.1038\/s41598-018-22229-5"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Huang F, Zhao Y, Wang Q, et al. Dapagliflozin attenuates renal tubulointerstitial fibrosis associated with type 1 diabetes by regulating STAT1\/TGF\u03b21 signaling. Front Endocrinol (Lausanne) 10: 441, 2019.","DOI":"10.3389\/fendo.2019.00441"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Mise K, Hoshino J, Ubara Y, et al. Renal prognosis a long time after renal biopsy on patients with diabetic nephropathy. Nephrol Dial Transplant 29: 109-118, 2014.","DOI":"10.1093\/ndt\/gft349"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Okada T, Nagao T, Matsumoto H, et al. Histological predictors for renal prognosis in diabetic nephropathy in diabetes mellitus type 2 patients with overt proteinuria. Nephrology (Carlton) 17: 68-75, 2012.","DOI":"10.1111\/j.1440-1797.2011.01525.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358: 580-591, 2008.","DOI":"10.1056\/NEJMoa0706245"},{"key":"25","unstructured":"25. Ueki K, Sasako T, Okazaki Y, et al.; J-DOIT3 Study Group. Effect of an intensified multifactorialintervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 5: 951-964, 2017."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/12\/59_4323-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T03:30:20Z","timestamp":1592623820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/12\/59_4323-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,15]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4323-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,15]]}}}